恒瑞医药：SHR-4298注射液获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the clinical trial of SHR-4298 injection, which will commence shortly [1] Group 1: Product Development - SHR-4298 injection is a self-developed Class 1 therapeutic biological product that has demonstrated good anti-tumor activity in preclinical animal models [1] - The drug is intended for the treatment of advanced solid tumors, and currently, there are no similar drugs approved for marketing domestically or internationally [1] - The total research and development investment for the SHR-4298 injection project has reached approximately 28.79 million yuan [1]